Search papers, query evidence, get expert commentary — all in one place
ACC 2026 Late-Breaking Trials
Live trial results, expert commentary, and discussion with 10+ trial authors
Does Transcatheter Tricuspid Valve Replacement (TTVR) improve safety and effectiveness at 30 days in real-world patients with severe TR?
Result: Thirty-day outcomes demonstrated acceptable safety, near-complete TR elimination, and significant health status improvements, with lower rates of new CIED implantation and bleeding than in randomized trials.

“Good performance of EVOQUE valve in this STS/ACC TVT Registry of Real-World Outcomes of Transcatheter Tricuspid Valve Replacement with >98% success but 16% new CIED w/o impact on 30 days outcomes. https://t.co/zipqHU6ho5”
These findings show that transcatheter tricuspid valve replacement is translating well from the clinical trial setting into routine practice across the United States. In a large, older and medically complex patient population, we saw very high procedural success, near-complete elimination of tricuspid regurgitation, and rapid improvement in how patients feel and function.
Does postmortem genetic testing identify pathogenic variants in Sudden Arrhythmic Death Syndrome cases?
Result: Postmortem genetic testing identifies pathogenic or likely pathogenic variants in a significant subset of SADS cases.
Result: Rapid progression occurred in 7.8% of patients with aortic sclerosis, 16.4% with mild AS and 29.8% with moderate AS.
Does bioprosthetic mitral valve replacement increase the incidence of infective endocarditis compared to mitral valve repair in patients undergoing mitral valve intervention?
Result: Infective endocarditis was significantly more common after surgical MV replacement than surgical MV repair (IRR 2.34, 95% CI 1.06-5.18, p=0.035), but not significantly different between transcatheter MV replacement and repair (IRR 1.56, 95% CI 0.73-3.34, p=0.250).
Result: The paper provides a detailed historical consideration of the medical literature from 1800 to trace the provenance and evolving understanding of spontaneous coronary artery dissection.
Does endovascular therapy improve post-thrombotic syndrome severity and health-related quality of life in patients with moderate or severe post-thrombotic syndrome and iliac-vein obstruction?
Result: Endovascular therapy led to less severe post-thrombotic syndrome and better health-related quality of life than standard care over a 6-month period, but with a higher risk of bleeding.

“Original Article: Endovascular Therapy for Post-Thrombotic Syndrome — A Randomized Trial (phase 3 C-TRACT trial) https://t.co/XgtK21vpsG Editorial: Stenting for Post-Thrombotic Syndrome — A Step Forward https://t.co/iO6yAK4jvd #SIR26TOR | @SIRspecialists https://t.co/O0PdvA7Wib”
Many patients with PTS suffer in silence because few physicians are aware of this complication or know how to effectively treat it. This study suggests that even severe PTS is, in fact, a treatable condition in many patients.
Prospective study examines lipid profiles and cardiovascular disease risk across genders, indicating different associations.
Is the lipid-core burden index (LCBI) measured using NIRS-IVUS associated with early progression of cardiac allograft vasculopathy in patients after heart transplantation?
What is the prevalence of HFpEF patients in Japan who meet obesity-related eligibility criteria for GLP-1RA and GIP/GLP-1RA?

“Soft glans after #penileprosthesis surgery: a patient-reported study of prevalence and clinical impact 👉 https://t.co/eMSzNz4AFW @ManchesterAndro @IPearce82 @PeteGrice @VaibhavModgil https://t.co/WCnXPP7lZe”
Does pulsed field ablation improve procedural efficiency, safety, and 1-year outcomes compared to cryoballoon ablation in adults undergoing pulmonary vein isolation for atrial fibrillation?
Result: PFA shortened procedure duration versus CBA (MD -11.50 min, 95% CI -15.39 to -7.62) and lowered 1-year total atrial arrhythmia recurrence (RR 0.79, 95% CI 0.66-0.94).

“#EHRA26 | Day 1 – Late-Breaking Trials Paroxysmal AF ablation takes centre stage as Juan Carlos Zerpa Acosta is joined by Sandrine Venier and David Birnie to discuss key late‑breaking data, including: 🔹 FACIL‑AF – Pulsed field ablation versus cryoballoon ablation in paroxysmal https://t.co/hV7TWcfcD3”
For me, the message is that PFA is a better energy source to perform PVI than the cryoballoon. I think over time, PFA will probably completely replace thermal energy.